AMC MCQ (CAT) population health & ethics questions

The National Cervical Screening Program recommends a primary HPV test (not cytology) from age 25, with a 5-yearly interval if the result is negative for oncogenic HPV. HPV vaccination reduces but does not eliminate risk, so screening is still required at the usual starting age. The HPV test has higher sensitivity for detecting oncogenic HPV than cytology, allowing a longer safe interval between screens.

• A. Vaccination lowers risk but does not replace the need for screening from age 25.
• B. Pap smears (cytology) are no longer the primary test; HPV testing is more sensitive and used first.
• C. Cytology alone every 3 years was the old Pap smear protocol, superseded by primary HPV testing.
• D. Annual screening is unnecessarily frequent and not recommended under the current program.

For women with HPV detected (non-16/18 oncogenic type) and reflex cytology showing a low-grade abnormality, the recommended management is repeat HPV testing in 12 months to assess for viral clearance, as most such infections resolve spontaneously. Colposcopy is reserved for HPV 16/18 positive results, persistent HPV infection at the 12-month repeat test, or high-grade cytological abnormality. This approach avoids unnecessary invasive procedures while ensuring appropriate follow-up for persistent infection.

• A. A 5-year interval only applies after a negative HPV test, not after a positive intermediate-risk result.
• B. There is no role for empirical antiviral or immune-modifying topical treatment in cervical screening management.
• D. Endometrial biopsy is irrelevant to cervical HPV screening results.
• E. Colposcopy is not first-line here; it is reserved for HPV 16/18, persistent infection, or high-grade cytology.

The National Bowel Cancer Screening Program uses the immunochemical faecal occult blood test (iFOBT), which detects human haemoglobin and is more specific than the older guaiac-based test. Average-risk asymptomatic Australians aged 50-74 years are invited to screen every 2 years using a home-collected iFOBT kit. Colonoscopy, sigmoidoscopy and CT colonography are not used as the population screening tool; they are reserved for investigation of a positive iFOBT or higher-risk groups.

• A. Colonoscopy is not the population screening test; it is used to investigate a positive iFOBT.
• B. Flexible sigmoidoscopy is not part of the national screening program.
• C. CT colonography is not used for average-risk population screening in Australia.
• D. The guaiac test is the older, less specific method and is not used in the current national program.

Any positive iFOBT result requires referral for colonoscopy, regardless of the absence of symptoms, because iFOBT positivity indicates occult blood loss that may reflect an adenoma or early-stage, often asymptomatic, colorectal cancer. Repeating the test is not recommended as it delays diagnosis and a negative repeat does not reliably exclude pathology. Colonoscopy allows direct visualisation, biopsy and removal of polyps, forming the diagnostic pathway after a positive screening test.

• A. CT abdomen and pelvis is not the recommended next investigation; colonoscopy is both diagnostic and therapeutic.
• B. Lack of symptoms does not exclude significant pathology; absence of symptoms should not delay colonoscopy.
• C. Faecal calprotectin assesses inflammatory bowel disease activity and has no role in the positive iFOBT pathway.
• D. Repeating the test is not recommended; a positive result mandates colonoscopy regardless of a subsequent result.

BreastScreen Australia offers free 2-yearly mammography to women aged 50-74 years, who are actively invited to participate, with women aged 40-49 and over 74 also eligible to self-refer. Biennial mammography has been shown to reduce breast cancer mortality in this age group through early detection of asymptomatic disease. Annual screening is not recommended for average-risk women as it increases false positives and radiation exposure without proportional benefit.

• A. MRI is reserved for women at high familial risk, not average-risk population screening.
• B. Screening is designed to detect asymptomatic disease before a lump is palpable, so waiting for a lump defeats its purpose.
• C. Ultrasound is not the primary screening modality in the national program.
• E. Annual mammography is not recommended for average-risk women in the national program.

Women with a confirmed BRCA1 or BRCA2 mutation are classified as being at high familial risk and require annual mammography combined with annual breast MRI, typically beginning from age 30-35 or earlier depending on family history, rather than waiting for the standard population screening age. MRI has higher sensitivity in younger women with dense breast tissue and in mutation carriers who have elevated lifetime risk. This intensified, earlier protocol falls outside the standard BreastScreen population program and is coordinated through a familial cancer or high-risk breast clinic.

• A. Ultrasound alone is insufficiently sensitive for surveillance in confirmed BRCA mutation carriers.
• C. Mammography alone misses cancers that MRI detects in younger, high-risk women with dense breast tissue.
• D. A confirmed pathogenic mutation mandates proactive surveillance, not a wait-for-symptoms approach.
• E. Standard population screening from age 50 is inadequate for a confirmed high-risk mutation carrier.

Unlike cervical, bowel and breast cancer, there is no organised national screening program for prostate cancer because evidence on the balance of benefits and harms of PSA testing is less clear-cut. Current guidelines recommend that clinicians engage in shared decision-making, discussing the potential benefits (early detection) and harms (overdiagnosis, overtreatment, biopsy complications, anxiety) so the patient can make an informed choice. This respects patient autonomy while ensuring the decision is evidence-based rather than driven by anecdote alone.

• A. Biopsy is an invasive diagnostic procedure and is never a first step without a preceding PSA result and clinical correlation.
• B. Ordering the test without discussion ignores the ethical requirement for informed, shared decision-making.
• C. Restricting testing to symptomatic men is overly restrictive; the discussion should occur based on patient request and risk factors, not only symptoms.
• D. PSA testing is not prohibited; it can be offered after informed discussion of benefits and harms.

The Australian absolute CVD risk calculator stratifies 5-year risk as low (<10%), moderate (10-15%) and high (>15%), or automatically high-risk if certain clinical criteria are met (e.g. diabetes with microalbuminuria, stage 3 CKD, familial hypercholesterolaemia, prior CVD event). A calculated 5-year risk of 12% without any automatic high-risk criteria falls into the moderate risk band, which prompts lifestyle modification with reassessment in 6-12 months before considering pharmacotherapy.

• A. High risk requires a 5-year calculated risk above 15% or an automatic high-risk clinical criterion, neither of which is present.
• B. "Mild risk" is not a recognised category in the Australian absolute CVD risk framework.
• C. An ECG is not required to calculate or interpret absolute cardiovascular risk using the standard chart.
• D. Low risk is defined as a 5-year risk below 10%, which does not apply here.

An AUSDRISK score of 12 or more indicates high risk of developing type 2 diabetes within 5 years and warrants fasting blood glucose or HbA1c testing to screen for undiagnosed diabetes or pre-diabetes. A score below 12 allows reassurance with lifestyle advice and periodic rescreening. The oral glucose tolerance test is reserved for cases where fasting glucose or HbA1c results are equivocal or borderline, not as the initial test.

• B. A score of 14 is above the threshold of 12 and requires biochemical testing now, not simple reassurance.
• C. Pharmacological prevention is not indicated based on a risk score alone without confirmed pre-diabetes or diabetes.
• D. Oral glucose tolerance testing is not the recommended first-line investigation; fasting glucose or HbA1c is used initially.
• E. A random glucose level is less reliable than fasting glucose or HbA1c for screening purposes.

For asymptomatic adults without additional risk factors, the RACGP Red Book recommends that absolute cardiovascular disease risk assessment, which includes a lipid profile, blood pressure and glucose testing, begins at age 45 years (age 35 for Aboriginal and Torres Strait Islander people) and is repeated every 5 years if the result is low risk. This interval balances early detection of dyslipidaemia and cardiovascular risk against the burden of unnecessary testing in a low-risk population. More frequent testing is reserved for those with risk factors or an abnormal initial result.

• A. Age 35 is the recommended starting age for Aboriginal and Torres Strait Islander people, not the general average-risk population, and the interval given is also too long.
• B. Annual testing is more frequent than recommended for an average-risk asymptomatic adult and is not supported by guidelines.
• C. Deferring until age 65 would miss over two decades of opportunity for risk stratification and early intervention.
• D. Waiting for symptoms is inappropriate since dyslipidaemia and early atherosclerosis are typically asymptomatic.

Current Australian guidelines recommend basing the decision to start statin therapy on absolute cardiovascular risk rather than LDL-cholesterol level alone, since overall risk integrates multiple factors including age, blood pressure, smoking status and lipid profile. A 5-year absolute risk above 15% is classified as high risk and warrants pharmacotherapy in addition to lifestyle measures, even if LDL-cholesterol is only modestly elevated. This patient has already undertaken an adequate trial of lifestyle modification without sufficient risk reduction, making statin therapy the appropriate next step.

• B. Delaying treatment for a further 12 months is inappropriate given his high absolute risk and failed lifestyle trial.
• C. LDL-cholesterol level alone should not determine treatment; absolute risk is the primary driver of the decision in this framework.
• D. Fish oil supplementation has not been shown to reduce cardiovascular risk sufficiently to replace statin therapy in high-risk patients.
• E. Coronary calcium scoring is not routinely required when absolute risk is already clearly in the high-risk category.

The Australian Immunisation Handbook provides specific catch-up schedules for children and adults who are incompletely vaccinated or have no documentation, based on their current age rather than restarting from birth. Catch-up vaccination aims to bring the person up to date as quickly and safely as possible using the recommended minimum intervals between doses, rather than the standard intervals used in the routine schedule. Serology-guided approaches are not standard practice for determining catch-up needs in children, and delaying vaccination leaves the child unnecessarily susceptible to preventable disease.

• A. Skipping earlier missed doses would leave him inadequately protected against diseases covered by those vaccines.
• B. Serology testing before vaccination is not standard practice and would unnecessarily delay protection.
• C. Waiting until school entry age unnecessarily prolongs his period of susceptibility to vaccine-preventable diseases.
• D. Restarting from birth is unnecessary and not recommended; catch-up schedules are based on current age.

MMR is a live attenuated vaccine and is contraindicated during pregnancy because of the theoretical risk of transmission to the fetus, even though no confirmed cases of vaccine-associated congenital rubella syndrome have been reported. Women who are inadvertently vaccinated in pregnancy or become pregnant shortly after vaccination require counselling but not routine termination, as the actual risk appears to be very low. In this case, vaccination should be deferred until after delivery, with her rubella immune status checked and managed postpartum. Reassurance and monitoring for rubella symptoms, along with appropriate serological testing if exposure is confirmed, are the priorities during the pregnancy itself.

• A. Varicella vaccine is also a live vaccine and is equally contraindicated in pregnancy.
• B. Rubella exposure itself is not an indication to override the contraindication to live vaccines in pregnancy.
• C. There is no recommended reduced-dose protocol for administering live vaccines in pregnancy; it remains contraindicated regardless of dose.
• D. Checking rubella IgG status does not change the contraindication to administering a live vaccine during pregnancy.

The Australian Immunisation Handbook recommends that a pertussis-containing vaccine (dTpa) be given to pregnant women ideally between 20 and 32 weeks of gestation, regardless of prior vaccination history. This timing maximises the transplacental transfer of maternal antibodies to the fetus, providing passive protection against pertussis during the vulnerable early months of life before the infant completes their own primary vaccination series. Vaccination outside this window, including in the first trimester or after 32 weeks, results in less effective antibody transfer, and vaccination after delivery does not protect the infant directly.

• A. Vaccination in the first trimester does not allow adequate time for optimal transplacental antibody transfer before birth.
• B. Vaccination after delivery does not provide any passive protection to the newborn through placental transfer.
• D. dTpa should be given in every pregnancy regardless of previous vaccination history, as antibody levels decline over time.
• E. Waiting until 36 weeks or later reduces the time available for antibody transfer to the fetus before delivery.

The recombinant zoster vaccine (RZV) is a non-live, adjuvanted subunit vaccine and is safe for use in immunocompromised people, unlike the live attenuated zoster vaccine, which is contraindicated in this group. The Australian Immunisation Handbook recommends RZV for adults aged 65 years and over, and from age 18 years for people who are immunocompromised or at increased risk of herpes zoster. This patient is on long-term immunosuppressive therapy (methotrexate and prednisolone) and is eligible on both age and immunocompromise grounds. Vaccination should not be delayed, as the risk of zoster and its complications is increased by her immunosuppression.

• A. She already meets the age-based eligibility criterion (65 years and over) regardless of her immunocompromise.
• B. Immunocompromise is an indication for the recombinant (non-live) vaccine, not a contraindication to all zoster vaccines.
• C. Delaying vaccination leaves her at ongoing increased risk of zoster; the recombinant vaccine can be given while immunosuppressed.
• D. The live attenuated vaccine is contraindicated in immunocompromised patients due to risk of disseminated vaccine-strain infection.

Anaphylaxis following a vaccine dose is a serious adverse event requiring referral to a specialist immunisation or vaccine allergy service to confirm the causative component and determine whether future doses can be safely given, potentially with a modified schedule, graded dosing or an alternative product. The Australian Immunisation Handbook specifies that anaphylaxis after any vaccine warrants specialist assessment before further doses, rather than an automatic blanket contraindication or an unmodified repeat dose. Simple antihistamine premedication does not address the risk of a further severe IgE-mediated reaction. Switching brands without assessment does not account for shared components causing the allergy.

• A. A true contraindication to all further doses is only declared after specialist assessment confirms this; it is not an automatic blanket rule.
• C. Giving the vaccine again without precautions ignores the proven anaphylaxis risk and is unsafe.
• D. Antihistamine premedication alone does not prevent recurrence of anaphylaxis and is not an adequate substitute for specialist review.
• E. Switching vaccine brands without assessing the specific allergenic component risks exposing the infant to the same allergen.

Refugee and humanitarian entrants with incomplete or uncertain vaccination records should be vaccinated according to the National Immunisation Program catch-up schedule, which calculates the number and timing of remaining doses based on age and documented vaccination history rather than starting over or waiting for specialist review. This approach counts the two documented pertussis-containing doses and determines the minimum additional doses and intervals needed to achieve age-appropriate protection. Catch-up schedules are funded under the National Immunisation Program for people under 20 years of age. Routine age-based scheduling alone would miss vaccines he should have already received, and restarting from birth is unnecessary and not recommended when valid documented doses exist.

• A. Restarting from birth is unnecessary when there is documented evidence of valid prior doses.
• C. Serology is not routinely recommended to determine immunisation status before vaccination in this setting; documented history should guide catch-up.
• D. This would miss vaccines and doses he should have already received in earlier childhood that are not part of the routine age-based schedule.
• E. Specialist review is not required before beginning routine catch-up vaccination in an otherwise well child.

The recommended approach to vaccine hesitancy is a respectful, non-judgemental conversation that explores the specific concerns driving hesitancy, provides accurate evidence-based information such as the lack of any causal link between vaccination and autism, and uses shared decision-making to build trust over time. Dismissing, coercing or threatening parents is likely to entrench distrust and reduce the chance of eventual vaccination, and is not supported by RACGP or Australian Immunisation Handbook guidance. There is no legal mandate forcing vaccination in Australia, although the No Jab No Pay policy links some family payments to immunisation status, which can be discussed as one relevant consideration. This is not medical neglect warranting a child protection report, as declining vaccination alone does not meet that threshold.

• A. Refusing care damages the therapeutic relationship and removes the opportunity to address her concerns over future visits.
• B. Avoiding the topic abandons an opportunity to correct misinformation and support an eventual informed decision.
• C. There is no legal compulsion to vaccinate in Australia, and this approach is coercive and inaccurate.
• E. Declining vaccination alone does not constitute medical neglect warranting a child protection notification.

The Aboriginal and Torres Strait Islander Adult Health Check, billed under Medicare Benefits Schedule item 715, can be claimed once every 12 months for Aboriginal and Torres Strait Islander people of any age from 15 years, aiming to detect and manage chronic disease risk factors early. It is a comprehensive assessment covering physical, psychological and social wellbeing, immunisation status, and preventive health screening appropriate to age and risk. Given this patient had her last check 11 months ago, she would become eligible for the next check at the 12-month mark rather than immediately. This health check is not limited to older adults and should be offered from adolescence onward given the higher burden of chronic disease at younger ages in this population.

• A. It is an annual health check intended for repeated use, not a one-off assessment.
• C. The correct minimum interval under Medicare rules is 12 months, not 2 years.
• D. The Medicare rebate for this item is available only once every 12 months, not every 3 months.
• E. The check is available from age 15 years, not restricted to older adults.

Secondary prophylaxis for rheumatic fever with carditis and valvular damage requires benzathine penicillin G 900 mg (1.2 million units) given intramuscularly every 4 weeks, continued for at least 10 years after the most recent episode of acute rheumatic fever or until age 21 years, whichever is longer, and often longer still with moderate-to-severe valve disease. Four-weekly intramuscular benzathine penicillin provides more reliable prevention of recurrent group A streptococcal infection and further rheumatic heart disease progression than oral regimens, which have poorer adherence and efficacy. A single dose or a short oral course treats an acute infection but does not provide the sustained protection needed to prevent recurrences over years. For patients with carditis, the duration is longer than for those with rheumatic fever without carditis, reflecting the higher risk of ongoing cardiac damage.

• A. A short oral course treats an acute streptococcal infection but does not provide ongoing secondary prophylaxis against recurrence.
• B. This dose and frequency are too infrequent and the duration too short for standard secondary prophylaxis with carditis.
• C. Oral amoxicillin is not the standard regimen; intramuscular benzathine penicillin is preferred for reliable secondary prophylaxis.
• E. A single dose only treats the current episode and provides no ongoing protection against recurrence.

Otitis media, particularly chronic suppurative otitis media, occurs at very high rates and at younger ages in Aboriginal and Torres Strait Islander children compared with the general population. The main concern driving surveillance programs is that persistent middle ear effusion and tympanic membrane perforation cause conductive hearing loss during critical periods of speech, language and cognitive development. Early detection through regular otoscopy and tympanometry allows timely referral for treatment, preventing long-term educational and social disadvantage. This is why ear health checks are embedded in child health schedules for Aboriginal and Torres Strait Islander children.

• A. Tonsillectomy is not the main intervention targeted by ear health surveillance.
• B. Otitis media surveillance targets hearing outcomes, not interrupting person-to-person transmission.
• C. Mastoiditis is a rare complication and not the main driver for population-level surveillance.
• D. Cholesteatoma is an uncommon complication, not the primary target of surveillance programs.

Culturally safe practice requires engaging a qualified interpreter, ideally through an Aboriginal language interpreter service, rather than relying on family members, who may misinterpret medical terminology, introduce bias, or cause the patient embarrassment regarding sensitive health information. Accurate communication about diagnosis, informed consent and management is a fundamental ethical and legal requirement, particularly when a new diagnosis such as diabetes is being discussed. Interpreter services funded through programs such as the National Aboriginal and Torres Strait Islander Interpreter Service should be accessed whenever a language barrier is identified, regardless of time pressures. This supports informed decision-making and reduces the risk of miscommunication-related harm.

• A. Partial translation by a family member still carries the same risks of inaccuracy and breached confidentiality.
• C. Family members as interpreters risk inaccurate translation, loss of confidentiality and patient discomfort discussing personal health matters.
• D. The patient has not been offered or declined a professional interpreter; this has not occurred.
• E. Gestures and simplified English do not ensure accurate understanding of a significant new diagnosis.

The gap in life expectancy is primarily attributed to social determinants of health rather than biological or genetic factors. Remote communities often experience compounding disadvantage, including overcrowded housing, lower employment and income, limited access to fresh food, and reduced access to primary health care and specialist services, all of which widen health inequities. This pattern is consistent with the social determinants of health framework used in Closing the Gap reporting, which identifies structural and historical factors, including the ongoing impacts of colonisation, as key drivers rather than individual-level genetic differences.

• A. Remote areas generally have reduced, not greater, access to bulk-billed services due to workforce shortages.
• B. There is no evidence of a genetic basis for the life expectancy gap; social determinants are the recognised primary driver.
• D. Remote communities generally have higher, not lower, rates of chronic disease contributing to the gap.
• E. This statement about income support rates is not an established or relevant explanation for the geographic gap.

The Closing the Gap PBS Co-payment Measure allows Aboriginal and Torres Strait Islander patients with, or at risk of, chronic disease to access PBS medicines at a reduced co-payment or free of charge, without needing to hold a concession card, provided they are registered with a general practice participating in the program (such as through Indigenous health identification on the practice register). This measure aims to reduce a key access barrier, medicine cost, that contributes to poorer chronic disease outcomes in this population. Eligibility is not restricted to specific chronic conditions or to rural or remote residence; it applies broadly to the management of existing or emerging chronic disease.

• B. Concession card status is not a requirement for this specific measure, which is designed to remove that barrier.
• C. The measure applies in both urban and rural/remote settings, not exclusively rural or remote areas.
• D. A Health Care Card is not required under this measure; registration through the practice is sufficient.
• E. The measure applies broadly to chronic disease management, not solely to diabetes medicines.

Pertussis is a notifiable condition under state and territory public health legislation across Australia, and clinicians have a legal obligation to notify confirmed or suspected cases to the local public health unit as soon as practicable, usually within one to a few days depending on jurisdiction. This notification triggers public health action, including contact tracing, exclusion advice for childcare or school, and consideration of prophylaxis for vulnerable contacts, which is time-critical given pertussis is highly infectious, particularly to unvaccinated infants. Laboratories also notify certain conditions, but this does not remove the treating clinician's own statutory notification duty. Prompt notification is essential to limit onward transmission in the community.

• A. Notifying the school directly does not fulfil the legal public health notification requirement to the health authority.
• B. Laboratory notification, where it occurs, is supplementary and does not replace the clinician's own statutory duty.
• D. A single confirmed case meets the notification threshold; waiting for further cases is not appropriate or lawful.
• E. Delaying notification until treatment completion would significantly impair timely public health response and contact tracing.

This is a high-risk percutaneous exposure (hollow-bore needle, visible blood, deep injury) to a known HIV-positive source, and current guidelines recommend commencing HIV post-exposure prophylaxis with a triple antiretroviral regimen as soon as possible, ideally within 1 to 2 hours and no later than 72 hours after exposure, because efficacy diminishes with delay. An undetectable viral load substantially lowers but does not eliminate transmission risk, so prophylaxis should not be withheld on this basis alone. Baseline serology should be collected but must not delay initiation of prophylaxis given the time-critical nature of PEP efficacy. Hepatitis B and C status of the source and recipient should also be assessed, but HIV PEP is the most urgent intervention here given the exposure characteristics.

• A. Repeat viral load testing of the source is not practical in the immediate window and PEP should not await this result.
• B. Hepatitis B status and vaccination history should be assessed, but HIV risk from this high-risk exposure also requires prophylaxis.
• C. Baseline testing should be obtained but must not delay time-critical initiation of prophylaxis.
• E. An undetectable viral load reduces but does not abolish transmission risk; PEP is still indicated after a high-risk exposure.

Mesothelioma has a very long latency period, typically 20 to 50 years after first asbestos exposure, and risk remains elevated for the remainder of a person's life regardless of smoking status, since smoking does not meaningfully increase mesothelioma risk (unlike its strong synergistic effect with asbestos on lung cancer risk). The man's occupational history of unprotected exposure to asbestos cement products is a recognised risk factor, and this risk does not diminish simply because exposure ceased decades ago. Routine screening with CT is not currently recommended for asymptomatic individuals with past asbestos exposure, as no screening test has been shown to improve mesothelioma outcomes; instead, patients should be counselled about risk and symptoms, and advised to seek prompt review if respiratory symptoms develop.

• A. Risk exists throughout life, not only if symptoms develop within a specific short time frame.
• B. Mesothelioma risk persists for decades after exposure ceases due to the long latency of the disease.
• D. Smoking status does not meaningfully affect mesothelioma risk, so this reassurance is not accurate.
• E. Routine screening CT is not currently recommended for asymptomatic asbestos-exposed individuals, as it has not been shown to improve outcomes.

Regular fluid intake of approximately 200-250 mL every 15-20 minutes is the key behavioural measure to prevent dehydration and heat illness in workers exposed to high ambient temperatures, and should continue throughout the shift rather than being guided by thirst alone, as thirst lags behind fluid deficit. Light-coloured, loose, breathable clothing is preferred over heavy dark clothing, which increases heat retention. Gradual acclimatisation over 1-2 weeks, not immediate full-intensity work, reduces heat strain. Routine salt tablet use is not recommended for well-nourished workers with normal dietary salt intake and can cause gastrointestinal upset and hypernatraemia.

• A. Routine salt tablet supplementation is not recommended and can cause gastrointestinal side effects without proven benefit for most workers.
• B. Heavy dark clothing increases heat absorption and retention, worsening heat strain.
• C. Relying on thirst underestimates fluid needs because thirst sensation lags behind the degree of dehydration.
• E. Sudden full-intensity work without acclimatisation increases the risk of heat illness; gradual acclimatisation over 1-2 weeks is recommended.

A bilateral sensorineural hearing loss with a characteristic 4000 Hz notch in a worker with a long history of occupational noise exposure and inadequate hearing protection is consistent with noise-induced hearing loss, which is a recognised and compensable occupational condition in Australia. The appropriate next step is referral for formal diagnostic audiometry (often through an accredited audiologist or occupational physician) to confirm the diagnosis and degree of loss, and to support a workers compensation claim under the relevant state scheme. Age-related presbycusis typically produces a gradually sloping high-frequency loss without the classic notch and should not be assumed without proper assessment. Oral corticosteroids are indicated for sudden-onset sensorineural hearing loss, not a chronic occupational pattern, and MRI is reserved for asymmetric or unilateral findings suggestive of a retrocochlear lesion.

• A. Fitting hearing aids without formal diagnosis and compensation assessment would miss the opportunity to document and claim for an occupational condition.
• B. The bilateral notched pattern and clear occupational exposure history make noise-induced hearing loss more likely than simple presbycusis, and the claim deserves proper work-up.
• C. Corticosteroids are used for sudden idiopathic sensorineural hearing loss, not for a chronic, gradually progressive occupational hearing loss.
• D. MRI is indicated for asymmetric or unilateral sensorineural loss to exclude a vestibular schwannoma, not for this symmetrical bilateral pattern.

Fitness-to-drive certification must be based on the Assessing Fitness to Drive national standards and the doctor's clinical judgement of risk to the patient and the public, not on the patient's financial pressures or preferences. The doctor's ethical obligation is to explain the reasoning transparently, outline the pathway to review (such as treatment of the sleep apnoea and reassessment), and decline to certify fitness if the criteria are not met. Certifying someone as fit against clinical judgement breaches professional and legal obligations and risks harm to the patient and other road users. Deliberately referring for a more favourable opinion or indefinitely deferring the decision avoids the doctor's duty rather than fulfilling it.

• A. Referring solely to seek a more lenient opinion undermines the integrity of the assessment process and does not reflect genuine clinical need.
• B. Documenting disagreement does not resolve the ethical problem of certifying someone as fit when the clinical assessment indicates otherwise.
• C. Indefinitely deferring the decision avoids the doctor's duty to give a clear, evidence-based outcome and leaves the safety risk unaddressed.
• D. Certifying against clinical findings purely due to patient pressure breaches the national driving standards and risks harm to the patient and public.

Routine first antenatal visit bloods recommended by Australian guidelines include full blood count, blood group and antibody screen, rubella IgG, varicella IgG if history uncertain, syphilis serology, hepatitis B and C serology, HIV serology, and midstream urine culture, to identify women who need additional monitoring or intervention. Rubella serology identifies non-immune women so they can be advised about avoiding exposure in pregnancy and offered post-partum vaccination, since the vaccine is contraindicated during pregnancy. An oral glucose tolerance test is not part of routine first-visit screening and is usually performed at 24-28 weeks unless risk factors are present. Group B Streptococcus screening is performed at 35-37 weeks gestation, and nuchal translucency ultrasound is a first-trimester aneuploidy screening test performed at 11-13+6 weeks as part of combined first-trimester screening, not a routine first-visit blood test.

• A. Nuchal translucency ultrasound is performed between 11 and 13+6 weeks as part of combined first-trimester aneuploidy screening, not as a first-visit blood test.
• C. GBS vaginal-rectal swab screening is performed later in pregnancy, at 35-37 weeks gestation.
• D. Maternal serum alpha-fetoprotein alone is not part of routine first-trimester screening in current Australian antenatal protocols.
• E. Fasting OGTT for gestational diabetes is routinely performed at 24-28 weeks, not at the first antenatal visit, unless risk factors warrant earlier testing.

Women with risk factors for gestational diabetes, including obesity (BMI greater than 30 kg/m2) and a previous macrosomic baby (birthweight over 4.5 kg), should be offered an early oral glucose tolerance test in the first or early second trimester, in addition to the standard test at 24-28 weeks if the early test is normal. A normal fasting glucose at booking does not exclude gestational diabetes, which is diagnosed using the 75 g OGTT with specific glucose thresholds at fasting, 1 hour and 2 hours. HbA1c is not the recommended screening test for gestational diabetes because it reflects glycaemia over the preceding months and lacks sensitivity in pregnancy. Empiric drug treatment without a confirmed diagnosis is inappropriate, and delaying testing to the third trimester risks missing early gestational diabetes that would benefit from earlier intervention.

• B. HbA1c is not the standard screening test for gestational diabetes in pregnancy due to its lower sensitivity for pregnancy-related glucose changes.
• C. A single normal fasting glucose at booking does not exclude gestational diabetes; a formal OGTT is still indicated given her risk factors.
• D. Delaying testing until the third trimester misses the opportunity for earlier diagnosis and management in a high-risk woman.
• E. Empiric metformin is not appropriate without a confirmed diagnosis of gestational diabetes based on OGTT criteria.

Newborn bloodspot screening in Australia is recommended at 48 to 72 hours of age, after the infant has had adequate feeding, because some conditions screened for, such as phenylketonuria, are detected through metabolite accumulation that requires sufficient protein intake to be reliably identified. Testing too early, such as immediately after birth or at 24 hours, risks false negative results for metabolic conditions because affected metabolites may not yet have accumulated to detectable levels. Waiting until 6 weeks or 7 days delays diagnosis and treatment of serious but treatable conditions like congenital hypothyroidism and cystic fibrosis, where early intervention improves outcomes significantly.

• A. Delaying screening until 6 weeks significantly postpones diagnosis and treatment of serious conditions that benefit from early detection.
• B. Testing immediately after birth, before feeding, risks false negative results for conditions detected through metabolite accumulation.
• C. At 24 hours, feeding may be insufficiently established, and some metabolites may not yet be detectable at reliable levels.
• D. Delaying to 7 days unnecessarily postpones diagnosis and treatment for conditions where early intervention is critical to prevent complications.

The 18-month Key Ages and Stages check focuses on a holistic developmental surveillance assessment, including gross and fine motor skills, expressive and receptive language, and social-emotional development, alongside growth monitoring and anticipatory guidance for the parents. Pure tone audiometry is not practical or standard at this age; hearing concerns are assessed through history and observation of response to sound and language development, with the newborn hearing screen already having occurred shortly after birth. School readiness and pre-literacy assessment are relevant to checks closer to school entry, around 4-5 years. Formal autism diagnostic interviews are not part of routine universal screening at 18 months, although surveillance for red flags such as lack of social engagement or language delay should prompt further assessment or referral if concerns arise.

• A. School readiness and pre-literacy assessment are relevant closer to school entry, not at 18 months.
• B. Pure tone audiometry is not standard practice at 18 months; hearing is assessed through developmental and behavioural observation.
• C. A dental check alone is too narrow a focus and does not capture the broader developmental surveillance required at this age.
• D. A formal autism diagnostic interview is not part of routine universal 18-month surveillance, though concerning features should prompt targeted referral.

Current SIDS risk reduction guidelines recommend placing infants on their back to sleep from birth, in their own cot in the parents' room for at least the first 6-12 months, on a firm, flat mattress free from pillows, doonas, soft toys and loose bedding that could cause rebreathing or suffocation. Side sleeping is not recommended because infants can roll from their side onto their stomach, which increases SIDS risk. Stomach sleeping (prone position) significantly increases SIDS risk and is not advised despite parental concerns about reflux. Soft mattresses and pillows increase suffocation risk and are contraindicated. Bed-sharing increases SIDS risk, particularly in the first few months, and room-sharing without bed-sharing is the recommended safer alternative.

• A. Bed-sharing increases the risk of SIDS, especially in young infants; room-sharing without bed-sharing is recommended instead.
• B. Side sleeping is not recommended because infants can roll onto their stomach, increasing SIDS risk.
• C. Soft mattresses and pillows increase the risk of suffocation and rebreathing and should be avoided.
• D. Stomach (prone) sleeping significantly increases SIDS risk and is not recommended even for reflux concerns.

Capacity is decision-specific and assessed functionally: the patient must be able to understand the relevant information, retain it long enough to use it, weigh it in the balance to arrive at a decision, and communicate that decision. A patient can have capacity even when making a decision that others consider unwise, including refusal of life-saving treatment. Formal cognitive screening tools and global functioning are supportive but not determinative of capacity for a specific decision. Consistency of the refusal over time strengthens, but does not by itself establish, capacity.

• A. Agreement with the majority view is irrelevant; capacity does not require a 'reasonable' decision.
• B. Independent living and financial management reflect general functioning, not capacity for this specific decision.
• C. A normal MMSE score does not equate to capacity for a specific treatment decision; capacity is functional, not based on a screening score.
• E. Past ability to consent does not establish current capacity for a different, high-stakes decision.

Under the mature minor doctrine (Gillick competence), a minor can consent to medical treatment if the treating doctor assesses that she has sufficient understanding and intelligence to fully comprehend the nature, purpose and risks of the proposed treatment. There is no fixed age in Australia for this assessment; it depends on the individual minor's maturity and the complexity of the decision. Parental consent or notification is not required once competence is established, and confidentiality should be maintained unless there is a significant risk to the minor's safety. This doctrine is recognised across Australian jurisdictions following the Gillick and Marion's Case principles.

• A. Withholding effective ongoing contraception based on age alone ignores the assessed competence and clinical need.
• B. Requiring parental consent disregards the Gillick competence principle once the minor's understanding has been demonstrated.
• C. Contacting parents without the competent minor's consent breaches confidentiality and is not required once Gillick competence is established.
• D. Court referral is unnecessary for routine competent decisions; it is reserved for complex or contested treatment decisions such as some gender-affirming or non-therapeutic interventions.

In New South Wales, the Guardianship Act 1987 establishes a hierarchy of 'persons responsible': an appointed enduring guardian, then a guardian appointed by the Tribunal, then a spouse or de facto partner in a close continuing relationship, then an unpaid carer, then a close friend or relative. With no partner, carer or appointed guardian, the next closest relative with a close personal relationship, here his daughter, becomes the person responsible. This hierarchy exists so that urgent and routine treatment decisions can proceed without court or tribunal delay. The sister would only be considered if no closer relative such as the daughter were available.

• A. Ethics committees provide advice and support but are not legal substitute decision-makers under guardianship legislation.
• B. Tribunal appointment is not required when a person responsible can be identified under the existing hierarchy; this would cause unnecessary delay.
• C. The daughter, as a closer relative with regular contact, ranks above the sister in the hierarchy regardless of age.
• D. Treating clinicians cannot substitute their own judgement for a legally recognised person responsible except in genuine emergencies where no substitute decision-maker is reasonably available.

A valid, current and applicable advance care directive has the same legal standing as a contemporaneous decision made by a competent patient and takes precedence over the wishes of family members or substitute decision-makers. For a directive to apply, it must have been made voluntarily by a person with capacity, and the clinical situation must match what was anticipated in the directive. Family input can inform understanding of a patient's values but cannot override a valid directive. Failing to honour a valid refusal of treatment constitutes battery and is both an ethical and legal breach.

• A. Family wishes, however well-intentioned, cannot override a valid and applicable advance care directive under Australian law.
• B. Providing treatment against a valid directive, even temporarily, breaches the patient's prior autonomous refusal.
• C. Tribunal involvement is unnecessary when a valid and applicable directive already exists and is confirmed; this would cause harmful delay.
• D. Advance care directives made with proper capacity and voluntariness are legally binding, not merely advisory, in jurisdictions that recognise them.

Valid informed consent in Australia requires that the patient be given information about the diagnosis, the nature and purpose of the proposed treatment, material risks (those a reasonable patient would want to know, or that the particular patient has indicated are important, per Rogers v Whitaker), alternative options including no treatment, and expected benefits. The patient must have capacity, receive this information, and consent voluntarily without coercion. Disclosure of the surgeon's individual complication statistics, a cooling-off period, or an independent witness are not legal requirements for valid consent, though good practice may involve clear documentation.

• A. General practitioner sign-off is not a legal requirement for valid surgical consent.
• C. A witness is not a legal requirement for the validity of consent, although it may be used for documentation purposes.
• D. No mandatory cooling-off period is required for standard elective procedures in Australia.
• E. Surgeons are not legally required to disclose personalised complication statistics, although general risks relevant to the procedure must be discussed.

When a person with a suspected mental illness poses an immediate risk of serious harm to themselves or others and lacks capacity to consent to treatment due to that illness, involuntary assessment and treatment under the relevant state Mental Health Act is appropriate and legally authorised. This overrides the usual requirement for consent because the refusal itself is a product of impaired capacity from acute psychosis, and delay poses imminent danger. Family consent is not required for emergency involuntary assessment, and this process does not need prior tribunal approval, though tribunal review follows subsequent to the initial detention and treatment order under the Act's safeguards.

• B. Family presence is not a prerequisite for emergency involuntary assessment when risk is immediate.
• C. Tribunal applications occur as a review process after assessment and treatment orders are made, not as a precondition for emergency intervention.
• D. He has explicitly refused treatment and lacks capacity due to psychosis; implied consent does not apply here.
• E. Discharge is unsafe and inappropriate given his imminent risk of serious harm and lack of capacity to refuse care.

Confidentiality is not absolute: when a patient discloses a specific, credible and imminent threat to an identifiable third party, the treating clinician has an ethical and, in most Australian jurisdictions, a legal duty to take reasonable steps to protect that person, which may include warning the intended victim and notifying police. This exception is justified because the risk of serious harm to an identifiable individual outweighs the patient's interest in confidentiality. The disclosure should be limited to what is necessary to prevent the harm. Waiting, deferring to family, or seeking bureaucratic guidance would unacceptably delay action needed to prevent serious harm.

• B. Delaying action by a week fails to protect the identified victim from an imminent, specific threat.
• C. Confidentiality may be breached without consent when there is a serious, imminent and specific risk to an identifiable third party.
• D. The complaints commission handles complaints about health services; it is not the appropriate avenue for urgent risk management.
• E. Decisions about breaching confidentiality for public safety are the clinician's professional and legal responsibility, not the family's.

Doctors in Western Australia, as in all Australian jurisdictions, are mandatory reporters of suspected child physical abuse where they form a reasonable belief based on clinical findings and history. The inconsistency between the explanation given and the pattern of bruising, combined with the child's demeanour, meets the threshold of reasonable belief requiring an immediate report to the statutory child protection authority, without needing parental consent or further corroboration. Reporting obligations exist specifically to protect children and override the usual requirement for parental consent to disclosure, and delay or deferral to another clinician does not discharge the reporting doctor's personal legal obligation.

• A. Confronting the parent first may compromise any subsequent investigation and does not fulfil the mandatory reporting duty, which is triggered by reasonable belief, not parental explanation.
• B. Referral to a specialist does not discharge the reporting GP's own independent legal obligation to report.
• D. Delaying the report risks ongoing harm to the child and does not meet the legal obligation to report promptly once reasonable belief is formed.
• E. Parental consent is not required, and seeking it may alert an abusive parent and increase risk to the child.

Sensitivity is the proportion of people who truly have the disease (PCR-positive) who are correctly identified as positive by the test. Here, 100 patients are PCR-positive, and 85 of them test positive on the rapid antigen test, giving a sensitivity of 85/100 = 85%. Sensitivity is calculated only within the true-positive (disease-present) column of the 2x2 table, not against all test-positives or the total sample. Specificity, by contrast, would use the PCR-negative column (360/400).

• A. 360/400 is the specificity, using true negatives over all PCR-negative patients.
• B. 85/500 uses the entire study sample as the denominator, which is not a standard diagnostic accuracy measure.
• C. 85/125 uses the total number of rapid-test positives (true positives plus false positives) as the denominator, which calculates positive predictive value, not sensitivity.
• E. 360/375 uses the total number of rapid-test negatives as the denominator, which calculates negative predictive value.

Positive predictive value (PPV) is the proportion of positive test results that are true positives, and unlike sensitivity and specificity, it varies with disease prevalence (pre-test probability). As prevalence increases from 0.3% to 5%, the number of true positives relative to false positives rises, because there are proportionally more diseased individuals in the tested population. Sensitivity and specificity are fixed test characteristics that do not change with prevalence; only PPV and negative predictive value are prevalence-dependent. This is why the same test performs better predictively in a high-risk clinical population than in a low-risk screening population.

• A. Sensitivity does not rise with prevalence; it remains constant regardless of the population tested.
• B. This is incorrect; PPV is explicitly dependent on prevalence, unlike sensitivity and specificity.
• C. Specificity is an inherent test characteristic and does not change with disease prevalence.
• D. Sensitivity is an inherent test characteristic and does not change with disease prevalence.

Number needed to treat (NNT) is calculated as 1 divided by the absolute risk reduction (ARR). The risk of stroke in the treatment group is 40/500 = 8%, and in the placebo group is 80/500 = 16%, giving an ARR of 16% - 8% = 8% (0.08). NNT = 1/0.08 = 12.5, meaning approximately 13 patients need to be treated for 5 years to prevent one additional stroke. NNT is always reported with its associated time frame, as it reflects the duration of the trial from which it was derived.

• A. 2 corresponds to the relative risk (16%/8%), not the number needed to treat.
• B. 25 would result from using the relative risk reduction (50%) inverted incorrectly rather than the absolute risk reduction.
• C. 6.25 would result from halving the correct ARR incorrectly or miscalculating the risk difference.
• E. 8 corresponds to the percentage risk in the treatment group, not the NNT.

Relative risk reduction (RRR) of 30% applied to an absolute baseline risk of 8% gives an absolute risk reduction (ARR) of 0.08 x 0.30 = 0.024, or 2.4 percentage points, not a 30-percentage-point drop. The number needed to treat is 1/0.024 ≈ 42, meaning about 42 patients with this baseline risk need treatment for 5 years to prevent one myocardial infarction. Relative risk reductions sound more impressive than absolute risk reductions and can mislead patients with low baseline risk into overestimating personal benefit. Effective shared decision-making requires translating relative measures into absolute terms meaningful to the individual patient.

• B. This conflates relative and absolute risk; a 30% RRR does not mean his absolute risk falls by 30 percentage points.
• C. A 30% relative reduction still produces a real, if modest, absolute benefit even at low baseline risk; this does not mean no benefit exists.
• D. Trial-derived relative risk reductions are generally applicable to individuals with similar risk profiles when combined with their own baseline absolute risk.
• E. Relative risk reduction can be discussed, but it must be translated into absolute terms for meaningful individual counselling.

A GP Management Plan (GPMP, MBS item 721) combined with Team Care Arrangements (TCA, MBS item 723) is the appropriate mechanism for patients with chronic or terminal medical conditions who require ongoing care from the GP and at least two other collaborating health or care providers, such as a podiatrist, dietitian and diabetes educator. This patient's multiple chronic conditions (diabetes, hypertension, chronic kidney disease) and need for multidisciplinary input meet the eligibility criteria. The health assessment item is a separate, distinct service focused on preventive assessment and does not itself fund ongoing multidisciplinary coordination. GPMP/TCA items can be used alongside, but do not replace, an Aboriginal and Torres Strait Islander health assessment when both are clinically indicated.

• A. This initiative is specific to mental health care pathways and is not relevant to coordinating diabetes, hypertension and chronic kidney disease management.
• C. The health assessment item supports preventive screening and care planning but does not itself fund ongoing allied health team coordination in the way GPMP/TCA does.
• D. A standard long consultation does not provide structured, funded multidisciplinary coordination over 12 months.
• E. A review item requires an existing management plan to review; none exists yet, so an initial GPMP must be created first.

A case-control study is the most appropriate design for investigating a rare outcome such as hepatic angiosarcoma, because it identifies people who already have the disease (cases) and compares their past exposure to the solvent with that of disease-free controls. This design is efficient, time- and cost-effective for rare diseases, since a prospective cohort study would require an impractically large sample size and long follow-up to accrue enough cases. Case-control studies are particularly suited to rare outcomes with long latency, such as cancers linked to occupational exposures. They do, however, remain susceptible to recall and selection bias, which must be addressed in design.

• A. A prospective cohort study would require following an enormous and impractical number of exposed and unexposed workers for many years to accumulate enough rare cancer cases.
• B. Ecological studies examine population-level, not individual-level, exposure and outcome data, and are prone to ecological fallacy; they are not ideal for establishing individual causal association.
• C. Randomising people to a known or suspected carcinogen is unethical and not feasible for studying occupational exposure and cancer risk.
• E. A cross-sectional survey measures exposure and outcome at a single point in time and is poorly suited to establishing temporal sequence for a rare, slowly developing cancer.

Confounding is present when a third variable, here smoking, is associated with both the exposure (alcohol) and the outcome (oesophageal cancer), distorting the crude association; adjusting for it in a multivariable model changes the magnitude of the association, as seen here. Because the stratum-specific associations in smokers and non-smokers are similar in magnitude, there is no effect modification, which would instead show different magnitudes of association across strata. The key distinguishing feature is that confounding is addressed by statistical adjustment (producing a changed, usually attenuated, estimate), whereas effect modification is a biological phenomenon reported by presenting separate stratum-specific estimates rather than adjusted away. This distinction is important for correctly analysing and reporting observational data.

• B. Reverse causation refers to the outcome influencing the exposure rather than vice versa, which is not suggested by this stratification pattern.
• C. Selection bias arises from how study participants were chosen, not from the pattern of stratified association magnitudes described.
• D. Effect modification would be shown by differing strengths of association between alcohol and cancer across smoking strata, which is not seen here since the strata show similar magnitudes.
• E. Information bias arises from inaccurate measurement of exposure or outcome, which is not what is demonstrated by this stratified analysis.